1. In vivo diagnosis with purified tropomyosin in mite and shellfish allergic patients
- Author
-
M. Ángeles López-Matas, Sandra Vicario, Isabel Flores, Carmen Andreu, Luis Angel Navarro, Raquel Moya, Ángel Julio Huertas, Inmaculada María Sánchez-Guerrero, Carlos H. Larramendi, Angel Ferrer, Jerónimo Carnés, Maribel Peña, and José Luis García-Abujeta
- Subjects
Adult ,Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,animal structures ,Adolescent ,Immunology ,Tropomyosin ,macromolecular substances ,medicine.disease_cause ,Gastroenterology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Allergen ,In vivo ,Internal medicine ,Hypersensitivity ,Prevalence ,medicine ,Mite ,Animals ,Humans ,Immunology and Allergy ,In patient ,Shellfish ,Aged ,Skin Tests ,biology ,business.industry ,Pyroglyphidae ,Allergens ,Middle Aged ,biology.organism_classification ,medicine.disease ,Shrimp ,030104 developmental biology ,030228 respiratory system ,Spain ,Female ,business ,Anaphylaxis - Abstract
Background Tropomyosin is the most studied shellfish allergen and has been involved in cross-reactivity among different invertebrates (crustacean, mollusks, mites, insects, and nematodes). Objective To determine the relevance of tropomyosin in mite- and shellfish-sensitized patients using tropomyosin skin testing. Methods Patients were divided into 3 groups: group M included mite allergic patients (ie, individuals with respiratory symptoms and a positive result on skin prick testing [SPT] to house dust mites), group S included shellfish allergic patients (ie, individuals who reported symptoms with shellfish), and group MS included mite- and shellfish allergic patients (ie, individuals who simultaneously fulfilled the inclusion criteria for groups M and S). Tropomyosin was purified from shrimp, characterized, and used in SPT for diagnosis in the patient population. Results Eight hundred fifty patients were included in the study: 790 (92.9%) in group M, 21 (2.5%) in group S, and 39 (4.6%) in group MS. Tropomyosin was purified from shrimp with a purity higher than 95%. Forty-two individuals tested positive to tropomyosin: the prevalence was 2.7% in group M, 28.6% in group S, and 38.5% in patients of group MS. Twenty-one (50%) of the tropomyosin-positive individuals had symptoms with shellfish, and 3 (14.3%) reported anaphylaxis. Conclusion The prevalence of tropomyosin was low in mite-sensitized patients (2.7 %) and high in shellfish allergic patients (28.6%). The higher prevalence of tropomyosin was found in patients sensitized to both mite and shellfish (38.5%). The selection of tropomyosin-sensitized patients by SPT might help in the choice of appropriate treatments or management for these patients.
- Published
- 2016
- Full Text
- View/download PDF